The risk of incident lymphoma in patients with IBD receiving anti-TNF therapy remains controversial because few patients receive anti-TNF monotherapy; most of them are treated with thiopurines alone or combined with immunosuppressants and anti-TNF agents (73, 80). The gene discussed is TNF; the disease is inflammatory bowel disease.